ICP control Flashcards

(22 cards)

1
Q

REVISE

Clinical signs of Raised ICP

A
  • Headache, vomiting
  • Drop in GCS
  • Seizures
  • Hypertension, Bradycardia
  • Unresponsive pupils
  • Pappiloedema- UL/BL
  • ECG- Twave⬇️, ST segment ⬇️, QT prolongation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ICP Control: Tiered System
(J Clin Med, 2022)

A

A stepwise system for management of ⬆️ ICP where Tt modalities used are prioritised based on their efficacy and relative risks.
Safer Tt- lower tiers
Tt with significant SE- higher tiers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

🟢 Tier Zero – Initial ICU Management

A

i* Admit to ICU
ii* Stabilisation & evaluation:
iii* Airway support: I & V
iv* Sedation & analgesia ( for comfort, facilitate MV)
v* Seizure prophylaxis, monitoring (Art line, CVC, ICP, etc.)
vi* Avoid Hypotension, ⬇️Na, ⬆️thermia
vii* Serial clinical evaluations
viii* Optimise venous return

=>Targets:
* SpO₂ > 94%
* PaCO₂ 35–38 mmHg
* MAP 80–100 mmHg
* CPP 60–70 mmHg
* Temp < 38°C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Revise

🟡 Tier One – Escalation for ICP Control

A

I) Sedation & analgesia- for ICP control

2) PaCO₂: Maintain low-normal (35–38 mmHg)

3) CSF drainage via EVD
- -CPP-60-70mm hg

4) Osmotherapy:
* Mannitol or hypertonic saline (e.g., 3% NaCl)
-Maint. se osmolarity- 320mosm/kg,
Se Na- 155mmol/L

5) Seizure prophylaxis

6) Consider EEG monitoring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

🟠 Tier Two – If ICP Refractory to Tier One

A
  1. Trial dose of NMB- NDMR better than SUX
  2. Mild Hypocapnia- 32-35mm hg
  3. Assessment of cerebral autoregulation [⬆️MAP to ⬆️CPP- check if ICP ⬇️es–> if ICP ⬇️es–> autoregulation intact ; titrate MAP to CPP of 60-70mm hg]
    If autoregulation intact, fluids/ vasopressors to increase CPP to 60-70mm hg

Hypocapnia carries risk of cerebral ischemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

🔴 Tier Three – Rescue Therapy

A
  1. Mild Hypothermia-35-36
  2. Barbiturate Coma
  3. Decompressive craniectomy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

BTF Recommendations

A

=> Maintain ICP < 22 mmHg

=> Maintain CPP > 60 mmHg

Intracranial Hypertension (ICH) in TBI
-common complication of TBI
- Associated with significant morbidity & mortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tiered System Approach

A
  • Modalities are prioritised based on:
    • Effectiveness
    • Relative risk
    • Lower-tier interventions = lower risk
    • Higher-tier interventions = higher risk
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Advantages of Tiered System

A
  1. Allows clinicians to avoid unnecessary risk:
    • Thorough clinical assessment (before escalation)
    • Use of repeat neuro exam or imaging if needed to confirm pathology and justify escalation

II. May identify:
* Extracranial causes of raised ICP:
* Infection
* Respiratory deterioration
* Seizure
* Other medical disorders

III. Imaging might show:
* Lesions amenable to surgery or evacuation
* Avoiding unnecessary medical escalation

IV. Flexible Decision-Making
* Allows skipping or individualising therapy tiers
* Can omit a tier if next step more beneficial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Tier One Therapies – Side Effects

A

=> Osmotherapy: Both Mannitol & Hypertonic Saline may:
* Cause fluid and electrolyte derangements

=> EVD drainage: Prefer ICP-guided drainage, not scheduled/protocolised
* ⚠️ In significant brain edema, drainage can be:
- Technically difficult
-↑ risk of hemorrhage or misplacement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tier Two Therapy Considerations
I]. Mild Hypocapnia

A

=>Mild Hypocapnia (PaCO₂: 32–35 mmHg)
I)* Causes cerebral vasoconstriction → ↓ CBF
* Risk of focal cerebral ischemia
* If used, should be:
->Multimodally monitored using:
-> Global & focal cerebral O2 monitoring
> TCD
> SjvO₂
>PbtO₂
* ⚠️ Not widely available in all ICUs

II)* Raised pH →
-↓ blood flow to tissues
- Electrolyte derangements:
(↓ K⁺, ↓ Ca²⁺, ↓ PO₄³⁻)
-↑ risk of seizures

III)* Since CBF is lowest in first 24 hours post-injury: reasonable to avoid hypocapnia during this period

=>* CO2 < 30 mmHg:
* ⚠️ Only to be used temporarily as a bridge (e.g. before surgery)
* Examples:
- Cushing’s reflex
-Impending herniation
* Once stabilized, gradual return to normocapnia is critical–> Prevents rebound intracranial hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Neuromuscular Blockade (NMB) in ⬆️ ICP
Indications
Advantages
Disadvantages

A

=>Advantages:
* May lower ICP by 2–3 mmHg
* ↓ Ventilator asynchrony–> Improved venous return from thoracic vessels- may improve MAP–>CPP

=> Drawbacks:
↑ Risk of:
* Ventilator-associated pneumonia (VAP)
* ICU-acquired neuromuscular weakness (e.g. ICU myopathy)
* Prolonged ICU stay

✅** Indications for NMB:**
*⬆️ ICP not responding to TIER 1therapies
* Severe ARDS or lung contusion
* Abdominal compartment syndrome
* Procedures:
- Bronchoscopy
-Tracheal suctioning
*Hyperthermia due to ↑ CO₂ production (from excess muscle activity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

SPAR – Static Pressure Autoregulation Assessment

A

✅ Method:
* Record baseline MAP, ICP, and CPP
* Stabilise CPP at ≥ 60 mmHg
* Titrate vasopressors to increase MAP by **10mm hg –>Observe ICP response for a maximum of 20mins. **

⬆️MAP–> ⬆️ CPP–> Cerebral vasoconstriction–> ⬇️CBF–> ⬇️Cerebral Bld volume –> ⬇️ ICP

Interpretation:
* ↑ ICP with ↑ MAP → cerebral vasoconstriction fails → poor autoregulation mmHg

If autoregulation is intact- ⬆️ MAP via fluids/Vasopressors

=>Limitations:
* ICP may rise exponentially if SPAR is lost
* MAP elevation may be difficult (esp. trauma, myocardial injury, high baseline)
* SPAR status can change → requires repeat assessment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

🔴 Tier 3 Therapy –
Therapeutic Hypothermia
Q. Mechanism
Q. Cellular level effects
Q. Risks

A

💡 Mechanism: Target temp** 35- 36°C** (esp. brain temp)
* ↓ Metabolic demand
* ↓** Brain tissue inflammation

🔬 Cellular-level effects:
* ↓ Excitotoxicity
* ↓ Inflammatory response
* ↓ Cerebral edema (esp. cytotoxic edema)

⚠️ Risks of Hypothermia
*	Pneumonia
*	Cardiovascular complications:
*	Arrhythmias
*	↓ cardiac output
*	Coagulation dysfunction
*	Platelet impairment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Hypothermia cont..
Q. Evidence regarding Mild hypothermia
Q. Current recommendations

A

=> Clinical Trial Outcomes
* No mortality benefit seen in large RCTs
–>Eurotherm- stopped early due to Safety concerns
–> POLAR - No improvement in clinical outcomes

✅ Current Recommendation
*	Mild hypothermia only
*	Target temp: 35–36°C
*	<35°C is not recommended

Compared to other Tier 3 therapies Hypothermia may be more suitable for
* Patients not actively bleeding
* Not surgical candidates eg- medically managed ICP without craniectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Barbiturates in TBI

Q. Common agents used
Q. Mechanism of action in TBI
Q. Adverse effects

A

=>Common Agents:
* Thiopentone
* Phenobarbital

=>Mechanism:
*	Induce greater metabolic suppression vs. propofol/midazolam
*	Also possess:
  -	Antiepileptic properties$
  -	Neuroprotective effects (↓ cerebral metabolic demand, ↓ excitotoxicity) $

=>Adverse Effects of Barbiturates
* Hypotension, myocardial depression
* Often requires vasopressors to maintain CPP
* Immunosuppression
* Hepatic and renal dysfunction
* Hypokalemia (esp. during loading phase)
* Hyperkalemia during withdrawal (May become severe enough to need RRT)
* Suppressed pupillary light reflex
* ⚠️ Can mimic brainstem herniation → need for neuro exam via EEG
* Drug accumulation->Prolonged sedation → delayed extubation, prolonged ICU stay

17
Q

Barbiturates in TBI cont..
Q. How will you initiate barbiturate coma in TBI?
Q.** What are the goals of therapy?
Q. What is the End Point?
Q. How will you withdraw Barbiturate therapy?**

A

=>Initiating Barbiturate Therapy

💉 Dosing
* Test dose of thiopentone (250 mg bolus)
* Assess ICP response

* If ICP ⬇️es with maintainence of CPP→ continue
* Total bolus dose: ~3–5 mg/kg(max-5g)
* Continuous infusion: 3–8 mg/kg/hr
*EEG monitoring recommended

🎯 End Point
* Aim for burst suppression ≥ 50% on EEG
* Used to assess depth of metabolic suppression

Goals of Therapy
* Achieve ICP control with minimum effective dose

=>Maintain:
* Euvolemia
* Adequate CPP

⚠️ Withdrawal Strategy
* Gradual reduction over a few days to prevent rebound ICP increase

18
Q

Decompressive Craniectomy (DC)
Q. Indications
Q. Risks and Complications
Q. Evidence

A

=> Used for refractory ICP elevation

=>Indications: Ideal Candidates for DC
* Previously fit individuals
* Unilateral pathology
* Good medical and social support
* Early phase of illness
* Non-responders to other treatments

In Limited Resource Settings where advanced monitoring (e.g., ICP, EEG, PbtO₂) is not available:
* Use of basic measures such as:
- Scheduled hyperosmolar therapy
-Continuous infusion of 3% saline

*	Surgical options may be central to management
19
Q

Barbiturates vs Propofol / Midazolam

A

=>Barbiturates provide:
* More effective suppression of cerebral O₂ consumption.
* Better reduction in metabolic demand
* Neuroprotective advantages

=>Propofol disadvantages (especially in high doses):
*	Cardiovascular depression
*	Pancreatitis, lipemia, PRIS (Propofol Infusion Syndrome)
*	Hepatic dysfunction, Transaminitis     
*	Rhabdomyolysis, renal failure
*	Malignant arrhythmias
*	Cardiovascular collapse
*	Thought to be due to impaired mitochondrial function & lipid metabolism
20
Q

DC cont..

Q. Complications
Q. Evidence

A

Complications of Decompressive Craniectomy
* Infection
* Bleeding
* Transtentorial herniation
* Hydrocephalus
* Subdural hygroma

⚠️ Risks should be explained clearly to the patient’s family before the procedure.

21
Q

DC cont..
Q. Evidence

A

🔬 Trial Summaries:

  1. DECRA Trial
    -> Early DC (ICP >20 mmHg for >15 mins)
    -> Outcome:
    • ↓ ICP but no mortality benefit
    • Worse functional outcomes vs conservative therapy
  2. RESCUEicp Trial
    ->DC used after ICP >25 mmHg refractory to medical therapy including hypothermia
    -> Findings:
    • ↓ mortality
    • ↑ survivors with severe disability, but
    • Also ↑ chance of favorable outcomes at 12 months
22
Q

Use of Tiered approach

A

**Use of the tiered approach:
i) When possible, use the lowest tier
ii) Move to the next tier if the ICP remains raised (CPP below 60-70)
iii) It is not necessary to use all the modalities within a tier before moving to the next tier
iv) Tiers can be skipped if this is considered advantageous
**